<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SCU-WestChina skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SCU-WestChina</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>index</TITLE></P><DIV class="bottom-wrapper"><DIV class="content-mid-wrapper"><DIV class="mytitle">
                Blocking the Urate Storm in the Blood
            </DIV><DIV class="sub-title">
                SCU-WestChina 2017 Project
            </DIV><DIV class="content-wrapper"><DIV class="content-title">
                    Abstract
                </DIV><DIV class="content-abstract">
                    Hyperuricemia and refractory gout are caused by the high urate concentration in the blood. Considering there are still debates
                    on whether the drug should be used in the asymptomatic hyperuricemia patients and the drug resistance
                    of the refractory gout patients, new approaches are eagerly needed. We constructed the urate metabolic
                    pathway in the probiotic <I>E. coli</I> Nissle 1917 and applied it in the gut to reduce the urate concentration
                    in the blood indirectly. In addition, we built a dialysis-like device combined with modified bacteria
                    to utilize the urate directly in the blood. Our solutions provide a suitable, long-term and non-drug
                    treatment for the asymptomatic hyperuricemia patients and an ultimate treatment for the refractory gout
                    patients.
                </DIV></DIV><DIV class="summary-nav"><DIV class="img-block"><DIV class="img-title">Background</DIV></DIV><DIV class="img-block"><DIV class="img-title">Project</DIV></DIV><DIV class="img-block"><DIV class="img-title">Modeling</DIV></DIV><DIV class="img-block"><DIV class="img-title">Human Practice</DIV></DIV><DIV class="img-block"><DIV class="img-title">Notebook</DIV></DIV><DIV class="img-block"><DIV class="img-title">Team</DIV></DIV><DIV class="img-block"><DIV class="img-title">InterLab</DIV></DIV></DIV><DIV class="summary-content-list"><DIV class="summary-content">
                    Uric acid is the end product of purine metabolism in human. Increased production or decreased excretion of uric acid can
                    lead to its accumulation in the body, causing hyperuricemia. If sodium urate crystals deposit from super-saturated
                    extracellular fluids to joints, synovium or other tissues and organs, it will cause a syndrome clinically
                    known as &quot;gout&quot;. Controversy still exists on whether to use medications on asymptomatic hyperuricemia,
                    refractory gout can be still hard to treat even with the new drug. And those are the reasons why we start
                    our project.
                    <A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/Background">More
                        </A></DIV><DIV class="summary-content">
                    Based on the background, our project will put forward a new method to control hyperuricemia and treat refractory gout from
                    the following two aspects: 1. Control of ordinary hyperuricemia (in the intestinal tract); 2. Treatment
                    of refractory gout when Pegloticase treatment is of no avail (with methods of dialysis)
                    <A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/Description">More
                        </A></DIV><DIV class="summary-content">
                    We used the insulator to measure the expression of eGFP driven by 10 Anderson's promoters for the first time. We updated
                    the information of the constitutive promoter family with quantitative protein data. The data is used
                    for our project modeling to construct the pathway.
                    <A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/Model">More
                        </A></DIV><DIV class="summary-content">
                    We collected the information from various tubes. As a medical school team, we got the first-hand feedback from clinical doctors
                    to make our project really meaningful. And it's our duty to spread the medical knowledge to the public
                    to practice the saying: &quot;Health related, life entrusted.&quot;
                    <A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/HP/Silver">More
                        </A></DIV><DIV class="summary-content">
                    &quot;Wit beyond measure is a man’s greatest treasure.&quot; — Luna Lovegood, <I>Harry Potter and the Order of the Phoenix</I><A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/Notebook">More
                        </A></DIV><DIV class="summary-content"><A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/Team">More
                        </A></DIV><DIV class="summary-content">
                    How close can the numbers be when fluorescence is measured all around the world?
                    <A class="link-more" href="https://2017.igem.org/Team:SCU-WestChina/InterLab">More
                        </A></DIV></DIV></DIV><DIV class="bottom-link"><DIV class="copy-link"><A href="#"><SPAN>© SCU-WestChina 2017 iGEM Team</SPAN></A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>